JPRN-jRCT2080225010已完成1 期
Phase I/II study to investigate safety and effectiveness at surgery using OIF/KX for patients with nonunion in femur, tibia or humerus.
Osteopharma Inc.0 个研究点目标入组 8 人开始时间: 2020年1月8日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 8
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 70age old(—)
- 性别
- Male
入选标准
- •1. The subject is 20 to 70 years old (when obtaining informed consent)
- •2. Patients with nonunion fracture in femur, tibia, or hummerus have been in nonunion for more 6 months since the fracture injury or the previous nonunion surgery, and need the surgery of autologous bonegraft.
- •3. Patients who are categorized to noninfected nonunion or non drainage and non active infected nonunion in Muller classification.
- •4. Patients who have general condition enough to undergo surgery, and are permitted to participate in the clinical study by investigator.
- •5. Patients who can understand the informed consent form and are willing to provide signature.
排除标准
- •Subjects will be excluded if ANY of the following exclusion criteria apply
- •1.Congenital pseudoarthrosis
- •2.Multiple pseudoarthrosis
- •3.Under radiation therapy, chemical therapy, or taking immunosuppressant
- •4.With movement paralysis in upper limb or lower limb of treatment (paralysis in lower limbs due to cerebral infarction, spinal cord injury, etc.)
- •5.Allergy or hypersensitive to calcium phosphatic
- •6.Malignant tumor or less than 5 years recurrence period after cancer treatment
- •7.Diabetes with uncontrollable blood glucose level medically by judgement of doctor.
- •8.Unstable angina, myocardial infarction, cerebral infarction, cerebral hemorrhage or transient ischemic attack less than 3 months after onset
- •9.Severe liver, renal, or heart disease
- •10.Autoimmune disease or history (excluding Hashimoto's thyroiditis or Graves'disease)
- •11.Patients who had or will have any other surgery on same extremity of nonunion within 30 days of nonunion surgery (exclude osteomyelitis, or external fixation removal)
- •12.Patients who participate in other clinical study (investigational product or device) at the enrollment
- •13.Registered in this clinical study in the past
- •14.Patients with Alcohol dependence or drug dependence
- •15.Any condition that is not suitable to participate in the study based on the physician's judgement.
- •16.Patients who have difficulty in the examination or follow-up designed in this study.
研究者
相似试验
已完成
1 期
Phase I/II study to evaluate the safety and efficacy of intrathecal injection of KP-100IT in subjects with acute spinal cord injurySpinal Cord InjuryJPRN-UMIN000014434Kringle Pharma, Inc.48
招募中
1 期
Gastric cancer S-1 dose optimization studyHER2-negative unresectable or advanced recurrent gastric cancerGastric cancer, HER2 negative, unresectable, advanced recurrenceD013274JPRN-jRCTs031230127Suzuki Nobumi20
招募中
1 期
A Phase I/II study to assess the safety and efficacy of full-spectrum medicinal cannabis plant extract 0.08% THC (NTI164) in the treatment of Rett syndrome (RTT)Rett SyndromeNeurological - Neurodegenerative diseasesACTRN12623000563662Fenix Innovation Group14
已完成
1 期
A clinical trial to study safety and effects of P276-00 in combination with Gemcitabine in treatment of pancreatic cancer .CTRI/2009/091/000214Piramal Life Sciences Limited23
撤回
2 期
A Phase I/II study to determine the safety and efficacy of a combination of anti-CD3 & anti-CD7 ricin A immunotoxins for treating steroid-resistant acute graft-versus-host disease.GVHDImmuunsysteemaandoeningen: acute omgekeerde afstotingsziekteacute graft-versus-host diseaseNL-OMON31737Henogen S.A.12
